TY  - JOUR
AU  - Casarrubios, Marta
AU  - Provencio, Mariano
AU  - Nadal, Ernest
AU  - Insa, Amelia
AU  - Del Rosario García-Campelo, María
AU  - Lázaro-Quintela, Martín
AU  - Dómine, Manuel
AU  - Majem, Margarita
AU  - Rodriguez-Abreu, Delvys
AU  - Martinez-Marti, Alex
AU  - De Castro Carpeño, Javier
AU  - Cobo, Manuel
AU  - López Vivanco, Guillermo
AU  - Del Barco, Edel
AU  - Bernabé, Reyes
AU  - Viñolas, Nuria
AU  - Barneto Aranda, Isidoro
AU  - Massuti, Bartomeu
AU  - Sierra-Rodero, Belén
AU  - Martinez-Toledo, Cristina
AU  - Fernández-Miranda, Ismael
AU  - Serna-Blanco, Roberto
AU  - Romero, Atocha
AU  - Calvo, Virginia
AU  - Cruz-Bermúdez, Alberto
PY  - 2022
DO  - 10.1136/jitc-2022-005320
UR  - http://hdl.handle.net/10668/20160
T2  - Journal for immunotherapy of cancer
AB  - Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for...
LA  - en
KW  - drug therapy, combination
KW  - gene expression profiling
KW  - immunotherapy
KW  - lung neoplasms
KW  - tumor biomarkers
KW  - Antineoplastic Agents, Immunological
KW  - B7-H1 Antigen
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease Progression
KW  - ErbB Receptors
KW  - Humans
KW  - Immunotherapy
KW  - Interferon Type I
KW  - Lung Neoplasms
KW  - Neoadjuvant Therapy
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
KW  - Receptor Protein-Tyrosine Kinases
KW  - Transcriptome
KW  - Tumor Microenvironment
TI  - Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
TY  - research article
VL  - 10
ER  -